Division of Allergy and Clinical Immunology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Mich; Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, Mich.
Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Mich.
J Allergy Clin Immunol. 2023 May;151(5):1145-1154. doi: 10.1016/j.jaci.2022.10.023. Epub 2022 Nov 22.
Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown notable progress. An increasing number of aspects of the immune system are being implicated in AD, including the epithelial barrier, T2 cytokines, and mast cells. Major advances in therapeutics were made in biologic cytokine and receptor antagonists and among Janus kinase inhibitors. We focus on these areas and address new insights into AD epidemiology, biomarkers, endotypes, prevention, and comorbidities. Going forward, we expect future mechanistic insights and therapeutic advances to broaden physicians' ability to diagnose and manage AD patients, and perhaps to find a cure for this chronic condition.
最近对特应性皮炎(AD)的病理生理学和治疗的研究取得了显著进展。越来越多的免疫系统方面被认为与 AD 有关,包括上皮屏障、T2 细胞因子和肥大细胞。在生物细胞因子和受体拮抗剂以及 Janus 激酶抑制剂方面,治疗学取得了重大进展。我们关注这些领域,并探讨 AD 流行病学、生物标志物、表型、预防和合并症的新见解。展望未来,我们预计未来的机制见解和治疗进展将扩大医生诊断和管理 AD 患者的能力,并可能为这种慢性疾病找到治愈方法。